COLEGIO SAN AGUSTIN BACOLOD

COLLEGE OF HEALTH AND ALLIED PROFESSIONS NURSING PROGRAM

DRUG STUDY
Name: Cassandra Michaella D. Cañete Date of Exposure: 02/10-13/2025
Year and Section: 4G Area of Exposure: TDH Week: 04
Group 25 Clinical Instructor: Cynthia Ruiz, RN, MN

GENERIC BRAND NAME CLASSIFICATIONS MECHANISM OF INDICATION ADVERSE EFFECT NURSING CONSIDERATIONS
NAME ACTION

dobutamine Dobutrex Pharmacotherapeutic: Direct-action Cardiac Overdose may produce Baseline Assessment:
Adrenergic agonist inotropic agent Decompensation severe tachycardia, and - Pt must be on continuous
Route: IV acting primarily on (Hemodynamic severe hypertension cardiac monitoring.
Clinical: myocardial beta1- support) - Determine weight (for dosage
Dosage: 2–20 Cardiac Stimulant adrenergic calculation).
mcg/kg/min receptors. - Obtain initial B/P, heart rate,
respirations.
Therapeutic Effect: - Correct hypovolemia before
Enhances drug therapy.
myocardial
contractility and Intervention/Evaluation:
increases heart rate. - Continuously monitor cardiac
rate, and arrhythmias.
- Maintain accurate I&O;
measure urinary output
frequently.
- Assess serum potassium,
plasma dobutamine
 (therapeutic range: 40–190
ng/mL).
- Monitor B/P continuously
(hypertension risk greater in pts
with preexisting hypertension).
- Check cardiac output, and
pulmonary wedge
pressure/central venous
pressure (CVP) frequently.
- Immediately notify physician of
decreased urinary output,
cardiac arrhythmias, significant
increase in B/P, heart rate, or
less commonly, hypotension.

verapamil Calan SR, Pharmacotherapeutic: Inhibits calcium ion Parenteral: Rapid ventricular rate in Baseline Assessment:
Verelan, Calcium channel entry across cardiac, Management of atrial flutter/fibrillation, - Obtain ECG, B/P, heart rate.
Route: PO, IV Verelan PM, blocker vascular smooth- supraventricular marked hypotension, - Record onset, type (sharp, dull,
Isoptin SR (nondihydropyridine) muscle cell tachyarrhythmias extreme bradycardia, HF, squeezing), radiation, location,
Dosage: membranes, dilating (SVT, rapid asystole, second- or intensity, duration of anginal
Oral: Clinical: coronary arteries, conversion to sinus third-degree AV block pain, precipitating factors
Hypertension: Antihypertensive, peripheral arteries, rhythm), temporary occur rarely. (exertion, emotional stress).
80–120 mg PO antianginal, arterioles. control of rapid
TID antiarrhythmic (class ventricular rate in Intervention/Evaluation:
Angina: 80–120 IV). Therapeutic Effect: atrial flutter/fibrillation. - Assess pulse for quality, rate,
mg PO TID Decreases heart rhythm.
rate, myocardial PO: Treatment of - Monitor B/P.
IV: contractility; slows angina at rest (e.g., - Monitor ECG for cardiac
Supraventricular SA, AV conduction. vasospastic angina, changes, particularly
tachycardia: 2.5– Decreases total unstable angina, prolongation of PR interval.
10 mg peripheral vascular chronic stable - Assess for peripheral edema.
resis tance by angina). Control of - For those taking oral form,
Stock: 10mg/tab vasodilation. ventricular rate at rest monitor daily pattern of bowel
and during stress in activity, stool consistency.
chronic atrial flutter
and/or fibrillation.
 Management of • Therapeutic serum level:
hypertension. 0.08–0.3 mcg/mL; toxic
Prophylaxis of serum level: N/A.
repetitive paroxysmal
supraventricular Patient/Family Teaching:
tachycardia (PSVT). - Do not abruptly discontinue
medication.
- Compliance with therapy
regimen is essential to control
anginal pain.
- Go from lying to standing
slowly.
- Avoid tasks that require
alertness, motor skills until
response to drug is
established.
- Limit caffeine.
- Avoid or limit alcohol.
- Report continued, persistent
angina pain, irregular
heartbeats, shortness of
breath, swelling, dizziness,
constipation, nausea,
hypotension.
- Avoid grapefruit products.

D5 0.3NaCl Pharmacotherapeutic: Dextrose and For replacement or - Fluid overload Baseline Assessment:
(5% Dextrose in Crystalloid IV Solution sodium chloride maintenance of fluid (edema, - Assess hydration status (skin
0.3% Sodium solutions are used and electrolytes hypertension, turgor, mucous membranes,
Chloride) Clinical: as sources of pulmonary urine output).
Parenteral Fluid electrolytes, calories congestion) - Monitor serum electrolytes
Route: IV Replacement, and water for - Electrolyte (sodium, potassium, glucose).
Electrolyte and Caloric hydration. Sodium imbalance - Check for signs of fluid
Stock: Solution and chloride ions are (hypernatremia, overload (edema,
1000mL/IV bag responsible for hyponatremia, hypertension, crackles in
regulating the acid- hypokalemia) lungs).
base balance of the - Hyperglycemia (due - Assess IV access site for
body. Dextrose is a to dextrose content) patency and signs of phlebitis
source of calories. It - Phlebitis or or infiltration.
is readily irritation at the IV
metabolised and site Intervention/Evaluation
helps to decrease - Dilutional - Monitor intake and output (I&O)
losses of body hyponatremia if to assess fluid balance.
protein and nitrogen. given in excess - Regularly check blood glucose
It also promotes levels, especially in diabetic
glycogen deposition patients.
and decreases or - Observe for signs of electrolyte
prevents ketosis. imbalance (confusion, muscle
weakness, irregular heartbeat).
- Watch for adverse reactions
such as fluid overload or IV site
complications.
- Administer at the prescribed
rate to prevent complications.

Patient/Family Teaching:
- Explain the purpose of IV
therapy and expected effects.
- Teach the patient to report any
pain, redness, or swelling at
the IV site.
- Advise on the importance of
monitoring blood glucose levels
if diabetic.
- Educate about potential side
effects like dizziness,
weakness, or swelling.